NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX) Could Be 41% Below Fair Value After Anktiva Optimism
ImmunityBio (IBRX) is back under the spotlight after investor optimism around its bladder cancer therapy Anktiva drove very large year to date share gains. Attention is now centered on regulatory and revenue timing questions.
See our latest analysis for ImmunityBio.
After a very large year to date share price return of 280.2%, ImmunityBio’s recent trading has cooled slightly, with a 7 day share price return decline of 6.6% and a 30 day share price return of 9.9%, keeping overall momentum...